Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.03M | -2.87M | -2.20M | -1.00M | -2.70M |
| Total Depreciation and Amortization | 27.70K | 27.70K | 27.70K | 27.70K | 27.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 77.20K | 623.80K | 9.30K | 31.50K | 42.90K |
| Change in Net Operating Assets | 1.78M | -578.80K | 425.70K | -229.90K | 269.30K |
| Cash from Operations | -1.14M | -2.80M | -1.74M | -1.17M | -2.36M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 669.30K | 794.80K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 7.35M | 0.00 | 0.00 | 0.00 | 4.04M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.02M | 794.80K | 0.00 | 0.00 | 4.04M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.88M | -2.00M | -1.74M | -1.17M | 1.67M |